Conference Day One
Wednesday 17th July 2024
8:00 am
Check-In & Light Breakfast
8:50 am Chair’s Opening Remarks
Enhancing Treatment Monitoring & Relapse Detection with Robust Liquid Biopsies for Quantifiable Clinical Impact
9:00 am Quantifying Clinical Impact by Evaluating Liquid Biopsy’s Role in Treatment Response Monitoring for Faster Relapse Detection
Synopsis
- Assessing the quantitative impact of liquid biopsy utilisation on patient outcomes in clinical trials to prove superiority over tissue biopsy
- Investigating the efficacy of DNA monitoring in therapy response assessment for faster relapse detection
- Addressing open questions surrounding the clinical utility of DNA based liquid biopsy for therapy monitoring and relapse identification
9:30 am Equity, Diversity & Inclusion (ED&I) Fireside Chat: Creating Awareness Amongst Decision Makers on Local & Global Disparities in Liquid Biopsy Research & Practice to Shape an Inclusive Future for Understudied Diseases
Synopsis
- How is the potential and utilization of liquid biopsies for new indications benefitting patients from diverse backgrounds?
- Why are certain populations underrepresented in studies harnessing liquid biopsy?
- What is being done to overcome the historical disparities and inequalities in liquid biopsy trials?
- How can the ED&I challenges be overcome by global and cross sector stakeholder collaboration for liquid biopsy research?
10:30 am
Morning Break & Speed Networking
Synopsis
As the European liquid biopsy community unites for the first time, this valuable session will ensure that you can connect with your peers in the room to make new and lasting connections.
Successfully Identify Novel Brain Biomarkers to Create Robust Precision Medicine Strategies for Improved Disease Management
11:30 am Navigating Precision Oncology by Integrating Metabolic Pathways for Novel Brain Tumour Therapeutics
Synopsis
• Identifying deranged metabolic pathways as therapeutic targets in brain tumours
• Leveraging metabolic vulnerabilities for personalized treatment strategies
• Future directions and prospects for precision oncology in brain tumour management
12:00 pm Exploring the New Era in Alzheimer’s Disease by Revolutionising Clinical Trials, Diagnosis & Treatment Via Biomarkers & Biology
Synopsis
• Tacking how historically, drug development for Alzheimer’s disease has suffered from a high attrition rate
• Redefining the disease from a clinical syndrome to a disease with biological definitions will support precision medicine approaches
• How fluid biomarkers have a critical role to play in this transformative era
12:30 pm
Networking Lunch Break
Leveraging Liquid Biopsy Tests to Enable Early Cancer Detection for Timely Intervention Increasing Treatment Success & Better Patient Care
1:30 pm Unlocking Precision Medicine in Early Clinical Translation Through the Role of Liquid Biopsies in Dose Optimization Within Project Optimus
Synopsis
• What are the key enablers for successful dose optimization in drug development?
• Liquid biopsy biomarker data demonstrating mode of action, safety and clinical efficacy
• Integration of liquid biopsy biomarkers with quantitative in silico modelling
• Learnings from a T-Cell bispecific molecule for patients with multiple myeloma
2:00 pm Roundtable Discussion: Leveraging Liquid Biopsy Testing in Early Cancer Detection for Timely Intervention to Enable Tailored Treatment Decisions
Synopsis
• Leveraging the presence of ctDNA as a prognostic indicator for treatment response and disease trajectory to optimize treatment plans, predict disease progression more accurately and ultimately save more lives?
• How to implement liquid biopsy for early cancer detection, emphasising the integration of liquid biopsy with complementary diagnostic modalities?
• How to improve patient surveillance to enable accurate surgical interventions particularly when tumours are more localised and less disseminated?
3:00 pm
Afternoon Networking Break & Scientific Poster Session
Revolutionising Disease Monitoring in Clinical Trials with Urine Assays & Flow Cytometry to Improve Biomarker Detection for More Personalised Treatments
4:00 pm Utilising Flow Cytometry as an Alternative Technology to Assess Minimal Residual Disease in Haematological Diseases
Synopsis
• How to use NK cells as markers to measure response
•Detecting indirect biomarkers in solid tumours
• Monitoring response in the clinic
4:30 pm Transforming Clinical Trials with Urine Assay Technology: A Promising Solution
Synopsis
• Detection in urine provides a non-invasive screening approach and mitigates certain challenges with tissue testing
• Early detection with urine-based assays in bladder cancer can lead to earlier treatment, better patient outcomes, and potentially a higher chance of cure
• Tumour markers in urine can also be utilized for disease monitoring and longitudinal response to treatment
• Urine offers rapidity, simplicity, and sensitivity in the mission of personalized medicine in bladder cancer